Back to Directory Madison O'Brien Email russell@frontierscience.org Phone +1 (716) 834-0900, ext 7356 Institution Frontier Science Foundation Address Frontier Science Foundation 4033 Maple Rd Amherst, NY 14226 USA Request an Update Affiliated Studies P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure and Immunotherapy Study Status Enrolling P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants DAIDS Number 10732 Research Area Tuberculosis IMPAACT 2046: UPLIFT Study DAIDS Number TBA Research Area Brain and Mental Health Study Status In Development IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Enrolling IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status In Development
P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure and Immunotherapy Study Status Enrolling
P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants DAIDS Number 10732 Research Area Tuberculosis
IMPAACT 2046: UPLIFT Study DAIDS Number TBA Research Area Brain and Mental Health Study Status In Development
IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Enrolling
IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status In Development